Search - tctmd.com

Displaying 81 - 100 of 104

Sort: Relevancy | Date

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Daily News

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Michael O'Riordan

November 26, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Todd Neale

November 10, 2018

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

Todd Neale

November 01, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content